Hepatitis C Therapy

Novartis acquires rights to Albuferon, a hepatitis C interferon drug set to enter phase III trials

Published in Hepatitis Weekly, July 3rd, 2006

Novartis announced the signing of an exclusive worldwide agreement with the U.S. biopharmaceuticals company Human Genome Sciences (HGSI) to acquire rights to Albuferon, an investigational drug about to enter phase III clinical trials for the treatment of chronic hepatitis C infections.

Novartis and HGS will copromote Albuferon (albumin interferon alfa-2b) in the U.S., while Novartis will have exclusive rights to market and promote it in the rest of the world. Phase III trials are expected to begin by the end of 2006.

Under the terms of the agreement, HGS will receive an upfront payment of US$45 million, with milestones payable at specific stages of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-07-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry